- Home
- AVDL
as 07-26-2024 4:00pm EST
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
| Founded: | N/A | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN |
| Market Cap: | 1.6B | IPO Year: | 1996 |
| Target Price: | $24.17 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.50 - $19.09 | Next Earning Date: | 08-07-2024 |
| Revenue: | $55,141,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 513.99% | Revenue Growth (next year): | 77.86% |
Stock Insider Trading Activity of Avadel Pharmaceuticals plc (AVDL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MCHUGH THOMAS S | AVDL | Chief Financial Officer | Jan 16 '24 | Buy | $14.50 | 2,000 | $29,000.00 | 80,500 | SEC Form 4 |
| McCamish Mark Anthony | AVDL | Director | Dec 28 '23 | Sell | $14.53 | 75,000 | $1,089,750.00 | 67,025 | SEC Form 4 |
Latest Avadel Pharmaceuticals plc News
AVDL Breaking Stock News: Dive into AVDL Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Avadel Pharmaceuticals to Join Russell 3000 Index Monday; Shares Rise After Hours
GlobeNewswire
a month ago
Avadel Pharmaceuticals to Join Russell 3000® Index
Zacks
a month ago
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
Motley Fool
2 months ago
VanEck Semiconductor ETF Is Riskier Than You Think
Motley Fool
2 months ago
A Wall Street Analyst Just Predicted Nvidia Would Hit a $10 Trillion Market Cap. Is That Actually Possible?
Reuters
2 months ago
Norway wealth fund to vote against Musk's $56 billion Tesla pay package
Simply Wall St.
2 months ago
Oberstdorfer Bergbahn Reports Full Year 2023 Earnings
GuruFocus.com
2 months ago
Director Gregory Pipkin Sells 82,238 Shares of Sable Offshore Corp (SOC)
Compare AVDL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVDL Avadel Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.